1. [Long-term survival in a case of recurrent gastrointestinal stromal tumor treated with intermittent or low-dose imatinib].
- Author
-
Kurata Y, Takaishi S, Sakuma Y, Iwasaki K, Nimura Y, Tohma T, Kagaya A, Yamamoto Y, and Matsubara H
- Subjects
- Aged, Antineoplastic Agents administration & dosage, Benzamides administration & dosage, Female, Gastrointestinal Stromal Tumors surgery, Humans, Imatinib Mesylate, Piperazines administration & dosage, Pyrimidines administration & dosage, Recurrence, Stomach Neoplasms pathology, Stomach Neoplasms surgery, Time Factors, Treatment Outcome, Antineoplastic Agents therapeutic use, Benzamides therapeutic use, Gastrointestinal Stromal Tumors drug therapy, Piperazines therapeutic use, Pyrimidines therapeutic use, Stomach Neoplasms drug therapy
- Abstract
A 65-year-old woman with a gastrointestinal stromal tumor(GIST)underwent a total gastrectomy in 1999. In 2004, she was diagnosed with an intra-abdominal recurrence and was treated with 300mg/day of imatinib. Because of the side effects of imatinib, we interrupted the treatment and were forced to reduce the dose from 300mg/day to 100mg/day. However, at present, the tumor remains controlled. In conclusion, this case suggested that, even if given irregularly or at a low-dose, continuous treatment with imatinib might contribute to long-term survival in patients with GIST.
- Published
- 2014